Skip to main content

Table 3 Adverse Events Reported by ≥2 Patients in Any Treatment Group (Safety Population)a

From: Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial

AE, n (%) CCH 0.25 mg
(n = 22)
CCH 0.40 mg
(n = 18)
CCH 0.60 mg
(n = 18)
Placebo
(n = 17)
Any AE 21 (95.5) 18 (100.0) 17 (94.4) 7 (41.2)
 Discontinuations due to AEs 0 0 0 0
 Any serious AE 0 0 0 0
 Contusion/bruising 13 (59.1) 9 (50.0) 9 (50.0) 1 (5.9)
 Extremity pain 10 (45.5) 10 (55.6) 7 (38.9) 1 (5.9)
 Local swelling 8 (36.4) 7 (38.9) 10 (55.6) 3 (17.6)
 Injection-site bruising 5 (22.7) 4 (22.2) 6 (33.3) 0
 Axillary pain 6 (27.3) 1 (5.6) 4 (22.2) 0
 Injection-site pain 4 (18.2) 4 (22.2) 2 (11.1) 0
 Injection-site swelling 5 (22.7) 4 (22.2) 0 0
 Injection-site pruritus 2 (9.1) 3 (16.7) 2 (11.1) 1 (5.9)
 Injection-site edema 2 (9.1) 0 2 (11.1) 0
 Pruritus 2 (9.1) 2 (11.1) 1 (5.6) 0
 Injection-site hemorrhage 2 (9.1) 0 1 (5.6) 0
  1. aPresented in order of occurrence in the active treatment groups
  2. AE adverse event, CCH collagenase clostridium histolyticum
\